• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » SuperSonic Imagine aims to reduce biopsies with ultrasound

SuperSonic Imagine aims to reduce biopsies with ultrasound

August 3, 2015 By Fink Densford

SuperSonic Imagine aims to reduce biopsies with ultrasoundFrench imaging company SuperSonic Imagine thinks its new imaging systems can change the biopsy game for the better, according to an interview with founder and chief strategic and innovation officer Jacques Souquet.

SuperSonic Imagine’s flagship device is the Aixplorer ultrasound imaging device which uses the company’s proprietary ShearWave elastography and UltraFast Doppler blood flow imaging.

Unlike other similar devices, SuperSonic’s uses software processing coupled with powerful processing boards produced by graphics company Nvidia, according to SuperSonic.

“Being able to simplify things changed the paradigm of the system, which is very much hardware centric, to a system where the intelligence is in the software. We built the software system – every function that is developed in hardware’s competitive environment is now in a software environment,” Souquet told MassDevice.com in an interview

While the idea isn’t unique to SuperSonic, Souquet said it is a 1st in medical imaging. The device, running off software, is able to analyze up to 20,000 frames per second. The number is too high for a human to visualize, but allows the software to do more with the data, Souquet said.

“Now, you cannot visualize 20,000 frames per second, but this enables us to do lots of processing in the background to further enhance the performance of the product. It also enabled us to create a new mode of imaging on top of the conventional mode every ultrasound does. This new mode enables us to measure the stiffness of tissue,” Souquet said.

The new mode allows doctors, who normally manually diagnose stiff tissue through physical touch and pressure, to find stiff tissue with a non-invasive ultrasound imaging device and reduce the possibility of invasive biopsies to verify their diagnosis.

“We can do it in a reproducible way and we can do it in a quantitative way. We do not depend on the expertise or skill of a physician to do it, it’s entirely automatic,” Souquet said.

To test the technology’s potential, the company initially focused on early breast cancer detection.  In a clinical study, 1,800 patients were scanned with the device and the scans were compared with biopsies from the same patients.

Souquet said that through the trial, the company found the device was accurate, gave reproducible results and could more specifically characterize the lesions as benign or malignant without losing any sensitivity to stiff tissue on the whole.

“It’s important to look at the breast biopsies in the United States. There are around 2 million biopsies in the U.S. nowadays. Of those biopsies, in 80% of them there is no cancer found. So you submit the patients to lots of anxiety, and on top of that there’s added cost to healthcare, as breast biopsies are not always needle punctures and are sometimes surgical,” Souquet said.

The American College of Radiology now includes ShearWave scans in their guidelines for breast cancer detection with ultrasound, Souquet said.

SuperSonic has since expanded the reach of the device, including detecting liver fibrosis, screening for prostate cancer, and for vascular indications using UltraFast Doppler. The company is looking at expanding to gynecological indications as well.

The result of its expanded indications has been a severe reduction in biopsies, Souquet said. Baylor, Texas-based liver expert Dr. James Trotter has reported a 90% reduction in biopsies since adopting SuperSonic’s Aixplorer, according to the company.

This reduction in biopsies to screen for liver fibrosis is important to the company, Souquet said.

“Liver biopsies are very painful, and the amount of complications out of liver biopsies is very high. It’s important now, with the invention of drugs, such as Hepatitis C drugs, to be able to monitor the patient during treatment,” Souquet said.

Souquet said the company’s devices are in more than 1,000 facilities worldwide and hopes the number will continue to grow.

The company is developing a next-generation modular platform for the device, which would allow the company to sell to more segments on the ultrasound market, Souquet said.

Filed Under: Imaging, Ultrasound Tagged With: SuperSonic Imagine S.A.

In case you missed it

  • Leading Medical UX Trends
  • Ex-Acclarent execs fined $1.5M in off-label marketing case
  • CDER head Woodcock to lead FDA for now
  • Prosecutors want to present evidence of Elizabeth Holmes’ quest for wealth and fame
  • TransEnterix raises more than $31M in stock offering
  • Boston Scientific launches WaveWriter Alpha spinal cord stim
  • What’s next for the FDA and for Stephen Hahn?
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
  • Medicare to cover breakthrough devices
  • FDA debuts plan for AI-based Software as a Medical Device
  • EU allows remote audits for medical devices during pandemic
  • Smith+Nephew sees Movemedical automating inventory for its sales people
  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Boston Scientific’s preliminary Q4 results show 6.8% revenue decline
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
  • FDA grants EUA for RapCov rapid COVID-19 antibody test
  • Former Corindus CEO Toland joins robotic `micro’ surgical startup

RSS From Medical Design & Outsourcing

  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. It comes in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]
  • Medicare to cover breakthrough devices
    FDA-designated breakthrough devices will have Medicare coverage the same day they are approved, under a final rule issued this week by the Centers for Medicare and Medicaid Services (CMS). The Medicare Coverage of Innovative Technology (MCIT) rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices… […]
  • FDA debuts plan for AI-based Software as a Medical Device
    The FDA today released its first plan to regulate artificial intelligence/machine learning (AI/ML)-based Software as a Medical Device (SaMD). The plan is a response to feedback received from the agency’s April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device.” It outlines five actions that the FDA… […]
  • EU allows remote audits for medical devices during pandemic
    The European Union has announced that it will temporarily allow remote audits of medical devices and in vitro diagnostics under the new regulations (MDR IVDR), set to go into effect on May 2021 and 2022 respectively. In a document published Monday, the European Commission agreed with industry and notified bodies that the ongoing COVID-19 pandemic… […]
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
    A new study in the Heart Rhythm Journal showed a magnetic charger for the iPhone 12 was able to deactivate a Medtronic implantable cardioverter defibrillator (ICD). The iPhone 12 has a circular array of magnets deployed around a central charging coil, making it compatible with the company’s wireless “MagSafe” accessories, according to the study published… […]
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
    Steris (NYSE:STE) announced today that it will acquire Cantel Medical (NYSE:CMD) for $4.6 billion — a major merger in the infection prevention space. The deal is expected to close by June 30, pending customary closing conditions, regulatory approvals and an OK by Cantel shareholders. News of the merger comes a month and a half after Steris closed… […]
  • How Abbott stayed two steps ahead of COVID-19
    Developing a fast COVID-19 that resembled a pregnancy test and building two factories to boost productions — those were but two of the quick-thinking actions that Abbott (NYSE:ABT) officials took in the early months of a deadly coronavirus pandemic. Abbott began tracking the virus in China at the end of 2019 and into early 2020. By February,… […]
  • BREAKING: Big medtech suspends political contributions in wake of Electoral College vote
    Just as they lined up to condemn last week’s attack on the U.S. Capitol, major medtech companies are suspending political contributions because of 147 federal lawmakers’ refusal to acknowledge the Electoral College win by President-elect Joe Biden and Vice President-elect Kamala Harris. Boston Scientific announced on Sunday that it has chosen to temporarily suspend its… […]
  • Neurofeedback could help prostheses feel lighter: Here’s how
    Researchers at ETH Zurich have developed a prosthesis system that connects to the body’s nervous system to help amputees perceive a prosthetic weight as lower. The prosthesis system provides feedback to the wearer using electrodes implanted in the thigh that are connected to the leg nerves. Information from the tactile sensors under the sole of… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS